DK1220830T3 - Anvendelse af elastase til åbning af obstruerede arterier og vener - Google Patents

Anvendelse af elastase til åbning af obstruerede arterier og vener

Info

Publication number
DK1220830T3
DK1220830T3 DK00965396T DK00965396T DK1220830T3 DK 1220830 T3 DK1220830 T3 DK 1220830T3 DK 00965396 T DK00965396 T DK 00965396T DK 00965396 T DK00965396 T DK 00965396T DK 1220830 T3 DK1220830 T3 DK 1220830T3
Authority
DK
Denmark
Prior art keywords
conduit
obstruction
elastase
veins
enzyme
Prior art date
Application number
DK00965396T
Other languages
Danish (da)
English (en)
Inventor
Nicholas F Franano
Original Assignee
Proteon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteon Therapeutics Inc filed Critical Proteon Therapeutics Inc
Application granted granted Critical
Publication of DK1220830T3 publication Critical patent/DK1220830T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Processing Of Meat And Fish (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00965396T 1999-09-24 2000-09-24 Anvendelse af elastase til åbning af obstruerede arterier og vener DK1220830T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15593899P 1999-09-24 1999-09-24
PCT/US2000/026237 WO2001021574A1 (en) 1999-09-24 2000-09-24 Systems and methods for opening obstructed biological conduits

Publications (1)

Publication Number Publication Date
DK1220830T3 true DK1220830T3 (da) 2007-07-16

Family

ID=22557384

Family Applications (3)

Application Number Title Priority Date Filing Date
DK00965396T DK1220830T3 (da) 1999-09-24 2000-09-24 Anvendelse af elastase til åbning af obstruerede arterier og vener
DK07008805T DK1923068T3 (da) 1999-09-24 2000-09-24 Systemer og fremgangsmåder til åbning af blokerede biologiske kanaler
DK10180533T DK2363142T3 (en) 1999-09-24 2000-09-24 Elastase for opening the closed biological channels

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK07008805T DK1923068T3 (da) 1999-09-24 2000-09-24 Systemer og fremgangsmåder til åbning af blokerede biologiske kanaler
DK10180533T DK2363142T3 (en) 1999-09-24 2000-09-24 Elastase for opening the closed biological channels

Country Status (11)

Country Link
EP (4) EP1923068B1 (cg-RX-API-DMAC7.html)
JP (2) JP5763286B2 (cg-RX-API-DMAC7.html)
AT (2) ATE511854T1 (cg-RX-API-DMAC7.html)
AU (1) AU7612100A (cg-RX-API-DMAC7.html)
CA (1) CA2385488C (cg-RX-API-DMAC7.html)
CY (3) CY1106656T1 (cg-RX-API-DMAC7.html)
DE (1) DE60034694T2 (cg-RX-API-DMAC7.html)
DK (3) DK1220830T3 (cg-RX-API-DMAC7.html)
ES (3) ES2364191T3 (cg-RX-API-DMAC7.html)
PT (3) PT1220830E (cg-RX-API-DMAC7.html)
WO (1) WO2001021574A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063838B1 (en) 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
CA2517006A1 (en) * 2003-02-20 2004-09-02 Proteon Therapeutics, Llc Methods for the treatment and prevention of diseases of biological conduits
JP2008513517A (ja) * 2004-09-22 2008-05-01 プロテオン セラペウチクス インコーポレーテッド 生物学的導管の疾患の治療方法及び予防方法
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
HUE046160T2 (hu) 2012-01-12 2020-02-28 Endo Global Ventures Clostridium histolyticum enzim
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
ES3036011T3 (en) 2017-03-01 2025-09-11 Endo Operations Ltd Apparatus and method for assessing and treating cellulite
CN118325876A (zh) 2017-03-28 2024-07-12 恩多风投有限公司 生产胶原酶的改进方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489261A (en) * 1981-01-26 1996-02-06 Trustees Of Boston University Hydrogels capable of supporting cell growth
US4636195A (en) * 1982-04-02 1987-01-13 Harvey Wolinsky Method and apparatus for removing arterial constriction
US4803294A (en) * 1987-10-29 1989-02-07 G. D. Searle & Co. Process and intermediates for the preparation of halogenated protease inhibitors
JPH0286777A (ja) * 1988-09-22 1990-03-27 Sankyo Co Ltd サル膵臓エラスターゼｉ
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
JP3054190B2 (ja) * 1989-01-27 2000-06-19 イムノリティックス・インコーポレイテッド 良性前立腺肥大処置のための組成物および方法
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
NL8900943A (nl) * 1989-04-14 1990-11-01 Euro Biopharm Technology B V Protease inhibitor.
US5318531A (en) * 1991-06-11 1994-06-07 Cordis Corporation Infusion balloon catheter
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5422261A (en) * 1993-04-16 1995-06-06 Baxter International Inc. Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
US5409926A (en) 1993-07-19 1995-04-25 Merck & Co., Inc. AT-2 antagonist inhibition of vascular restenosis
EP0815202B1 (en) * 1994-12-13 2007-02-21 Human Genome Sciences, Inc. Human tissue inhibitor of metalloproteinase-4
US6020181A (en) * 1995-05-17 2000-02-01 New York Blood, Inc. Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
US5830468A (en) * 1995-05-17 1998-11-03 The New York Blood Center, Inc. Fibrin(ogen) degradation by fibrinolytic matrix metalloproteinase
US5834449A (en) * 1996-06-13 1998-11-10 The Research Foundation Of State University Of New York Treatment of aortic and vascular aneurysms with tetracycline compounds
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors

Also Published As

Publication number Publication date
DE60034694T2 (de) 2008-01-17
EP1220830B1 (en) 2007-05-02
PT1923068E (pt) 2011-07-29
ATE511854T1 (de) 2011-06-15
JP2003523319A (ja) 2003-08-05
CY1117932T1 (el) 2017-05-17
DE60034694D1 (de) 2007-06-14
CY1112329T1 (el) 2015-12-09
CA2385488C (en) 2015-07-07
EP2332568A1 (en) 2011-06-15
EP2363142B1 (en) 2015-03-25
HK1162302A1 (en) 2012-08-31
PT1220830E (pt) 2007-06-11
ES2284528T3 (es) 2007-11-16
ES2534938T3 (es) 2015-04-30
WO2001021574A1 (en) 2001-03-29
ES2364191T3 (es) 2011-08-26
EP2363142B8 (en) 2015-06-10
EP2363142A1 (en) 2011-09-07
PT2363142E (pt) 2015-08-04
EP1220830A4 (en) 2005-03-30
DK1923068T3 (da) 2011-06-27
ATE361095T1 (de) 2007-05-15
EP1923068B1 (en) 2011-06-08
JP5793461B2 (ja) 2015-10-14
EP1220830A1 (en) 2002-07-10
JP5763286B2 (ja) 2015-08-12
JP2012131830A (ja) 2012-07-12
CA2385488A1 (en) 2001-03-29
DK2363142T3 (en) 2015-04-20
EP1923068A1 (en) 2008-05-21
CY1106656T1 (el) 2012-01-25
EP2363142A9 (en) 2011-10-19
WO2001021574A9 (en) 2002-12-27
AU7612100A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
DK0914102T3 (da) Præparater og fremgangsmåder til behandling eller forebyggelse af syddomme i legemskanaler
CY1112329T1 (el) Συστηματα και μεθοδοι για διανοιξη αποφραγμενων βιολογικων αγωγων
DE69833869D1 (de) Chirurgische endoskopische schneidvorrichtung
WO2003035142A3 (en) Catheter for modified perfusion
DE69638011D1 (de) Ngriff
DK0696456T3 (da) Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme
ITSV980070A0 (it) Sistema endovascolare per il trattamento delle stenosi carotidee e catetere per tale sistema.
WO1998049972A3 (en) Differential treatment of prosthetic devices
ATE458525T1 (de) Medizinisches system zur reduzierung vaskulärer obstruktionen
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE553721T1 (de) Erweitertes endovaskuläres transplantat
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
CY1109695T1 (el) Μικροοργανισμοι αποδομησης οξαλικου ή ενζυμα αποδομησης οξαλικου για την προληψη παθησης σχετιζομενης με οξαλικο
DE60042213D1 (de) Kathetervorrichtung zur behandlung von verkalkten vaskulären okklusionen
DE69841041D1 (de) Stent beschichtet mit dna
NO20044333L (no) Farmasoytiske kombinasjon for behandling av godartet prostatis hyperplasi eller for langtidsprevensjon av akutt urinretensjon
DE50308579D1 (de) Rundballenpresse
ES2114322T3 (es) Fluido de dialisis que contiene peptidos obtenidos de caseina como agentes osmoticos, e iones bicarbonato como agentes tamponadores.
DK0880964T3 (da) Aldosereduktaseinhibition til forebyggelse eller reversering af diabetisk cardiomyopati
TR200400424T4 (tr) IOP'nin kontrolü ve glokom tedavisi için 5HT2 agonistleri
BR0215389A (pt) Agente preventivo ou terapêutico para distúrbio urinário, método para prevenir ou tratar distúrbio urinário, uso de um composto, composto, pró-droga, processo para preparar o composto, medicamento, e, método para triar um composto
DK1331940T3 (da) Anvendelse af det lange pentraxin PTX3 til behandling af sygdomme forårsaget af ændret aktivering af vækstfaktoren FGF-2
ATE282089T1 (de) Inhibitorresistente serinproteasen
DK1222854T3 (da) Forebyggelse og behandling af sygdomme forbundet med blodkoagulering
BR0017168A (pt) Piranoindóis para tratamento de glaucoma